MA32774B1 - Antagonistes de récepteur de mélanocortine - Google Patents

Antagonistes de récepteur de mélanocortine

Info

Publication number
MA32774B1
MA32774B1 MA33818A MA33818A MA32774B1 MA 32774 B1 MA32774 B1 MA 32774B1 MA 33818 A MA33818 A MA 33818A MA 33818 A MA33818 A MA 33818A MA 32774 B1 MA32774 B1 MA 32774B1
Authority
MA
Morocco
Prior art keywords
melanocortin receptor
receptor antagonists
melanocortin
compound
composition
Prior art date
Application number
MA33818A
Other languages
Arabic (ar)
English (en)
Inventor
Sang Dae Lee
Sang Pil Moon
In Ae Ahn
Sung Pil Choi
Hyun Ho Lee
Dong Sup Shim
Soo Yong Chung
Hyun Min Lee
Koo Lee
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of MA32774B1 publication Critical patent/MA32774B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention concerne un composé ayant une bonne activité agoniste sur le récepteur mélanocortine, ou un sel pharmaceutiquement acceptable ou un isomère de celui-ci, et une composition agoniste pour le récepteur de mélanocortine comprenant celui-ci en tant que substance active.
MA33818A 2008-11-12 2011-05-05 Antagonistes de récepteur de mélanocortine MA32774B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080112403 2008-11-12
PCT/KR2009/006568 WO2010056022A2 (fr) 2008-11-12 2009-11-10 Antagonistes de récepteur de mélanocortine

Publications (1)

Publication Number Publication Date
MA32774B1 true MA32774B1 (fr) 2011-11-01

Family

ID=42165801

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33818A MA32774B1 (fr) 2008-11-12 2011-05-05 Antagonistes de récepteur de mélanocortine

Country Status (26)

Country Link
US (4) US8039622B2 (fr)
EP (1) EP2350060B1 (fr)
JP (1) JP5399506B2 (fr)
KR (1) KR101141976B1 (fr)
CN (1) CN102282141B (fr)
AR (1) AR074109A1 (fr)
AU (1) AU2009314827B2 (fr)
BR (1) BRPI0921063B8 (fr)
CA (1) CA2742248C (fr)
CL (1) CL2011001073A1 (fr)
CO (1) CO6362006A2 (fr)
CR (1) CR20110250A (fr)
EA (1) EA019146B1 (fr)
EC (1) ECSP11011026A (fr)
GE (1) GEP20135850B (fr)
IL (1) IL212468A0 (fr)
MA (1) MA32774B1 (fr)
MX (1) MX2011004583A (fr)
NZ (1) NZ592512A (fr)
PE (1) PE20110684A1 (fr)
TN (1) TN2011000222A1 (fr)
TW (1) TWI389903B (fr)
UA (1) UA99555C2 (fr)
UY (1) UY32238A (fr)
WO (1) WO2010056022A2 (fr)
ZA (1) ZA201103154B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
CA2825098C (fr) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine et derives de pyrazolopyrimidine en tant que modulateurs du recepteur de la melanocortine-4
HRP20211950T1 (hr) 2011-12-29 2022-03-18 Rhythm Pharmaceuticals, Inc. Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
RU2014145806A (ru) 2012-04-25 2016-06-10 Ф. Хоффманн-Ля Рош Аг Способы производства (3,4-дихлорфенил)-((s)-3-пропил-пирролидин-3-ил)-метанонгидрохлорида
CN103420981A (zh) * 2012-05-21 2013-12-04 中国医学科学院药物研究所 含有取代吡咯烷基的硫代吗啉类化合物
SG10202101510XA (en) 2015-09-30 2021-03-30 Rhythm Pharmaceuticals Inc Method of treating melanocortin-4 receptor pathway-associated disorders
EP3773897A1 (fr) 2018-04-06 2021-02-17 Rhythm Pharmaceuticals, Inc. Compositions pour le traitement d'une rénopathie
FI3953327T3 (fi) 2019-11-07 2024-01-31 Lg Chemical Ltd Melanokortiini-4-reseptoriagonisteja
JP2023548327A (ja) * 2020-10-29 2023-11-16 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法
WO2022092910A1 (fr) * 2020-10-29 2022-05-05 주식회사 엘지화학 Cristal de type ii d'un composé agoniste du récepteur de la mélanocortine et son procédé de préparation
EP4219471A4 (fr) * 2020-10-29 2024-03-13 Lg Chem, Ltd. Agoniste du récepteur de la mélanocortine-4 amorphe
KR102672626B1 (ko) 2020-10-29 2024-06-07 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅲ 및 이의 제조방법
WO2022092914A1 (fr) 2020-10-29 2022-05-05 주식회사 엘지화학 Forme cristalline iv de composé agoniste du récepteur de la mélanocortine et son procédé de préparation
US20240059652A1 (en) 2020-12-22 2024-02-22 Lg Chem, Ltd. Amorphous melanocortin receptor agonist and method for preparing same
US20240043407A1 (en) 2020-12-22 2024-02-08 Lg Chem, Ltd. Crystalline form i of melanocortin receptor agonist compound and method for preparing same
US20240051919A1 (en) * 2020-12-22 2024-02-15 Lg Chem, Ltd. Crystalline form iii of melanocortin receptor agonist compound and preparation method therefor
WO2022139444A1 (fr) 2020-12-22 2022-06-30 주식회사 엘지화학 Cristal de type ii d'un composé agoniste du récepteur de la mélanocortine et son procédé de préparation
CN116782877A (zh) * 2020-12-22 2023-09-19 株式会社Lg化学 作为黑皮质素-4受体的选择性激动剂的用途
TWI804170B (zh) * 2021-01-21 2023-06-01 南韓商Ｌｇ化學股份有限公司 黑皮質素-4受體促效劑的用途
WO2022182194A1 (fr) 2021-02-26 2022-09-01 주식회사 엘지화학 Agoniste du récepteur 4 de la mélanocortine
EP4317150A4 (fr) * 2021-05-06 2024-10-30 Lg Chem, Ltd. Forme cristalline vii d'un composé agoniste du récepteur de la mélanocortine et son procédé de préparation
EP4317149A4 (fr) * 2021-05-06 2024-08-21 Lg Chem, Ltd. Forme cristalline v d'un composé agoniste du récepteur de la mélanocortine et son procédé de préparation
JP2024516739A (ja) 2021-05-07 2024-04-16 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物とバニリンの共結晶およびその製造方法
JP2024517271A (ja) * 2021-05-07 2024-04-19 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の有機酸塩の結晶形ｉｖおよびその製造方法
WO2022235103A1 (fr) 2021-05-07 2022-11-10 주식회사 엘지화학 Cristaux de sulfate de composé agoniste du récepteur de la mélanocortine et leur procédé de production

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534503B1 (en) * 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
CA2377369A1 (fr) 1999-06-04 2000-12-14 Merck & Co., Inc. Piperidines substituees en tant qu'agonistes du recepteur de melanocortine-4
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
CA2403631A1 (fr) 2000-03-23 2001-09-27 Brenda L. Palucki Derives de spiropiperidine utilises comme agonistes du recepteur de la melanocortine
JP2003528088A (ja) 2000-03-23 2003-09-24 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬としての置換ピペリジン類
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
EP1320366A4 (fr) * 2000-08-23 2005-04-06 Merck & Co Inc Piperidines substituees en tant qu'agonistes de recepteurs de la melanocortine
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
CA2432985A1 (fr) 2001-01-23 2002-08-01 Vincent Mancuso Derives de piperazine et de piperidine en tant qu'agonistes du recepteur de la melanocortine
EP1368339A1 (fr) 2001-01-23 2003-12-10 Eli Lilly & Company Piperidines/piperazines substituees utilisees comme agonistes du recepteur de melanocortine
JP2004524297A (ja) 2001-01-23 2004-08-12 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニスト
AU2002250343B2 (en) 2001-02-28 2006-05-25 Merck Sharp & Dohme Corp. Acylated piperidine derivatives as melanocortin-4 receptor agonists
JP4104983B2 (ja) 2001-02-28 2008-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体
DE60215132T2 (de) 2001-02-28 2007-08-23 Merck & Co., Inc. Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten
PT1385823E (pt) 2001-04-09 2007-01-31 Novartis Vaccines & Diagnostic Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
WO2004078717A1 (fr) 2003-03-03 2004-09-16 Merck & Co., Inc. Derives de piperazine acylee tenant lieu d'agonistes du recepteur de la melanocortine-4
CN1764458A (zh) 2003-03-26 2006-04-26 麦克公司 作为黑皮质素－4受体激动剂的双环哌啶衍生物
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
WO2005047251A1 (fr) 2003-11-12 2005-05-26 Lg Life Sciences Ltd. Agonistes du recepteur de la melanocortine
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
WO2006019787A2 (fr) 2004-07-16 2006-02-23 Merck & Co., Inc. Derives de piperidine acyles, utilises en tant qu'agonistes du recepteur de la melanocortine 4
CN1988906A (zh) 2004-07-19 2007-06-27 默克公司 用作黑皮质素－4受体激动剂的酰基化哌啶衍生物
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1928460A2 (fr) 2005-08-01 2008-06-11 Pfizer Limited Nouvelles utilisations de composes d'agonistes du recepteur de mc4
EP1912968A1 (fr) 2005-08-04 2008-04-23 Pfizer Limited Composes piperidinoyl-pyrrolidine et piperidinoyl-piperidine
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2009510069A (ja) 2005-09-30 2009-03-12 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体作働薬としてのアシル化ピペリジン誘導体
AU2006304305B2 (en) 2005-10-18 2010-04-01 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2007131570A (ja) 2005-11-09 2007-05-31 Mitsubishi Pharma Corp 新規なアミノピロリジン誘導体
WO2007096186A1 (fr) 2006-02-23 2007-08-30 Santhera Pharmaceuticals (Schweiz) Ag Dérivés de phénylpipéridine substituée servant de modulateurs du récepteur de la mélanocortine-4.
CA2642922C (fr) 2006-02-23 2011-08-02 Pfizer Limited Piperidinoylpyrrolidines en tant qu'agonistes du recepteur de la melanocortine de type 4
ES2571253T3 (es) 2006-06-09 2016-05-24 Synact Pharma Aps Derivados de fenil pirrol aminoguanidina
TWI332501B (en) 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
AU2007300529A1 (en) 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Acylated piperidine derivatives as melanocortin-4 receptor modulators
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists

Also Published As

Publication number Publication date
NZ592512A (en) 2012-12-21
US8236955B2 (en) 2012-08-07
JP2012508730A (ja) 2012-04-12
US20110237795A1 (en) 2011-09-29
WO2010056022A3 (fr) 2010-09-10
CA2742248A1 (fr) 2010-05-20
EA201170676A1 (ru) 2011-12-30
AR074109A1 (es) 2010-12-22
EP2350060A2 (fr) 2011-08-03
CN102282141B (zh) 2014-09-10
GEP20135850B (en) 2013-06-10
CO6362006A2 (es) 2012-01-20
BRPI0921063B1 (pt) 2021-03-16
AU2009314827B2 (en) 2012-04-05
US20110224219A1 (en) 2011-09-15
US20100120783A1 (en) 2010-05-13
JP5399506B2 (ja) 2014-01-29
PE20110684A1 (es) 2011-09-28
AU2009314827A1 (en) 2010-05-20
MX2011004583A (es) 2011-06-01
ECSP11011026A (es) 2011-06-30
CL2011001073A1 (es) 2011-10-07
TN2011000222A1 (en) 2012-12-17
WO2010056022A2 (fr) 2010-05-20
ZA201103154B (en) 2012-01-25
UY32238A (es) 2010-01-05
IL212468A0 (en) 2011-06-30
TW201022246A (en) 2010-06-16
EP2350060B1 (fr) 2013-09-18
US8183243B2 (en) 2012-05-22
CR20110250A (es) 2011-08-26
US8039622B2 (en) 2011-10-18
TWI389903B (zh) 2013-03-21
BRPI0921063B8 (pt) 2021-05-25
EA019146B1 (ru) 2014-01-30
US8288386B2 (en) 2012-10-16
EP2350060A4 (fr) 2012-07-25
KR20100053458A (ko) 2010-05-20
US20110245500A1 (en) 2011-10-06
KR101141976B1 (ko) 2012-05-07
BRPI0921063A2 (pt) 2015-08-25
CA2742248C (fr) 2014-01-14
UA99555C2 (en) 2012-08-27
CN102282141A (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
MA32774B1 (fr) Antagonistes de récepteur de mélanocortine
NO20083630L (no) Nye pyridinderivater
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
EA201690033A2 (ru) Морфинановые соединения
MA34075B1 (fr) Composition pharmaceutique comprenant un dérivé pyrimidineone
EA201001230A1 (ru) Пестицидные смеси
WO2012030927A3 (fr) Formes galéniques à libération modifiée d'agonistes de 5-ht2c, utiles pour la gestion du poids
PT2040755E (pt) Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
CL2013000104A1 (es) Compuestos derivados de heterociclicos nitrogenados sustituidos, agonistas del receptor ip; composicion farmaceutica; combinación farmaceutica; y uso para el tratamiento de la hipertension arterial pulmonar.
SMT201600040B (it) Rilascio non covalente peptide-mediato di agenti attivi attraverso la barriera emato-encefalica
DE602007012072D1 (de) Orantagonisten
EA201170703A1 (ru) Производные адамантилбензамида
EA201270216A1 (ru) Фармацевтический состав
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
TW200942524A (en) Novel aminomethyl benzene derivatives
TW200942530A (en) Pyridine compounds
MX2010007807A (es) Mezclas de plaguicidas.
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
EA201001882A1 (ru) Гидроксизамещенные тиенопиримидиноны как антагонисты рецептора-i меланинконцентрирующего гормона
PA8814801A1 (es) Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos
CL2013000502A1 (es) Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
UA103996C2 (en) Ivabradine hydrobromide